Treatment of granuloma annulare and related granulomatous diseases with sulphasalazine: a series of 16 cases

Granuloma annulare (GA) and the related annular elastolytic giant cell granuloma (AEGCG) and interstitial granulomatous dermatitis (IGD) are idiopathic histiocytic inflammatory disorders, which are frequently recalcitrant to treatment.

[1]  Yu-Hung Wu,et al.  Spectrum and clinical variants of giant cell elastolytic granuloma , 2017, International journal of dermatology.

[2]  M. Rosenbach,et al.  Granuloma annulare: Pathogenesis, disease associations and triggers, and therapeutic options. , 2016, Journal of the American Academy of Dermatology.

[3]  M. Lebwohl,et al.  Treatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study. , 2016, Journal of the American Academy of Dermatology.

[4]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[5]  P. Gisondi,et al.  Interstitial granulomatous dermatitis: a distinct entity with characteristic histological and clinical pattern , 2012, The British journal of dermatology.

[6]  B. Dijkmans,et al.  Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis , 2012, Drugs.

[7]  J. Shapiro,et al.  Alopecia areata update: part II. Treatment. , 2010, Journal of the American Academy of Dermatology.

[8]  D. Khan,et al.  Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[9]  C. Limas.  The spectrum of primary cutaneous elastolytic granulomas and their distinction from granuloma annulare: a clinicopathological analysis , 2004, Histopathology.

[10]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[11]  R. Wolf,et al.  Miscellaneous treatments, I: sulfasalazine and pentoxifylline: unapproved uses, dosages, or indications. , 2002, Clinics in dermatology.

[12]  J. Case.  Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. , 2001, American journal of therapeutics.

[13]  N. Levine,et al.  Dapsone and sulfapyridine. , 2001, Dermatologic clinics.

[14]  R. Rodenburg,et al.  The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. , 2000, Arthritis and rheumatism.

[15]  J. V. D. van der Meer,et al.  Effects of antirheumatic agents on cytokines. , 1996, Seminars in arthritis and rheumatism.

[16]  E. Bissonnette,et al.  Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. , 1996, Journal of immunology.

[17]  A. Kettle,et al.  Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. , 1991, Biochemical pharmacology.

[18]  F. Shanahan,et al.  Sulfasalazine inhibits the binding of TNFα to its receptor , 1990 .

[19]  F. Shanahan,et al.  Sulfasalazine inhibits the binding of TNF alpha to its receptor. , 1990, Immunopharmacology.

[20]  R. Winkelmann,et al.  Generalized granuloma annulare: clinical and laboratory findings in 100 patients. , 1989, Journal of the American Academy of Dermatology.

[21]  B. McConkey,et al.  Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. , 1986, British medical journal.